BACKGROUND: Management of diabetes in pregnancy is burdensome due to self-glucose monitoring, recording, and reporting demands. Cellular-enabled glucometers provide real-time transmission of glucose values independent of internet access and cell phone data plans. We describe a quality improvement (QI) intervention that introduced cellular-enabled glucometers for use during pregnancies complicated by diabetes. METHODS: Our aim was to improve maternal glucose control in a cohort of insulin-requiring pregnant women enrolled in a telemedicine diabetes program. During initial establishment of a QI program, women were offered cellular-enabled glucometers but could elect to keep their standard meter. The primary outcome evaluated was glycosylated hemoglobin A1c (HbA1c) at delivery. RESULTS: Baseline characteristics including initial HbA1c were similar between women using a standard glucometer (n = 45) and those using a cellular-enabled glucometer (n = 72). Women who used a cellular-enabled glucometer had a lower HbA1c at delivery compared to those using a standard glucometer (5.8% vs 6.3%, P = .03). This improvement was particularly notable for women with poor glucose control (defined as HbA1c >6.5%) at initial obstetric visit. Women with poor glucose control who used a cellular-enabled glucose monitor had significantly lower HbA1c at delivery (6.0% vs 6.8%, P = .03) and greater change from initial visit compared to those using a standard glucometer (-2.6% vs -1.4%, P = .02). No statistically significant differences were detected in tracked neonatal outcomes. CONCLUSION: For pregnancies complicated by insulin-requiring diabetes, use of cellular-enabled glucometers as part of a perinatal diabetes program improves glucose control at delivery with timely transmission of accurate values throughout gestation.
BACKGROUND: Management of diabetes in pregnancy is burdensome due to self-glucose monitoring, recording, and reporting demands. Cellular-enabled glucometers provide real-time transmission of glucose values independent of internet access and cell phone data plans. We describe a quality improvement (QI) intervention that introduced cellular-enabled glucometers for use during pregnancies complicated by diabetes. METHODS: Our aim was to improve maternal glucose control in a cohort of insulin-requiring pregnant women enrolled in a telemedicine diabetes program. During initial establishment of a QI program, women were offered cellular-enabled glucometers but could elect to keep their standard meter. The primary outcome evaluated was glycosylated hemoglobin A1c (HbA1c) at delivery. RESULTS: Baseline characteristics including initial HbA1c were similar between women using a standard glucometer (n = 45) and those using a cellular-enabled glucometer (n = 72). Women who used a cellular-enabled glucometer had a lower HbA1c at delivery compared to those using a standard glucometer (5.8% vs 6.3%, P = .03). This improvement was particularly notable for women with poor glucose control (defined as HbA1c >6.5%) at initial obstetric visit. Women with poor glucose control who used a cellular-enabled glucose monitor had significantly lower HbA1c at delivery (6.0% vs 6.8%, P = .03) and greater change from initial visit compared to those using a standard glucometer (-2.6% vs -1.4%, P = .02). No statistically significant differences were detected in tracked neonatal outcomes. CONCLUSION: For pregnancies complicated by insulin-requiring diabetes, use of cellular-enabled glucometers as part of a perinatal diabetes program improves glucose control at delivery with timely transmission of accurate values throughout gestation.
Authors: Lene R Nielsen; Pia Ekbom; Peter Damm; Charlotte Glümer; Merete M Frandsen; Dorte M Jensen; Elisabeth R Mathiesen Journal: Diabetes Care Date: 2004-05 Impact factor: 19.112
Authors: M S Kramer; R W Platt; S W Wen; K S Joseph; A Allen; M Abrahamowicz; B Blondel; G Bréart Journal: Pediatrics Date: 2001-08 Impact factor: 7.124
Authors: Andrea Mosca; Renata Paleari; Maria G Dalfrà; Graziano Di Cianni; Ilaria Cuccuru; Giovanni Pellegrini; Lucia Malloggi; Matteo Bonomo; Simona Granata; Ferruccio Ceriotti; Maria T Castiglioni; Marco Songini; Giuliana Tocco; Michela Masin; Mario Plebani; Annunziata Lapolla Journal: Clin Chem Date: 2006-04-06 Impact factor: 8.327
Authors: Wai-Kit Ming; Lucy H Mackillop; Andrew J Farmer; Lise Loerup; Katy Bartlett; Jonathan C Levy; Lionel Tarassenko; Carmelo Velardo; Yvonne Kenworthy; Jane E Hirst Journal: J Med Internet Res Date: 2016-11-09 Impact factor: 5.428
Authors: Greg Ogrinc; Louise Davies; Daisy Goodman; Paul Batalden; Frank Davidoff; David Stevens Journal: BMJ Qual Saf Date: 2015-09-14 Impact factor: 7.035
Authors: Lucy Mackillop; Jane Elizabeth Hirst; Katy Jane Bartlett; Jacqueline Susan Birks; Lei Clifton; Andrew J Farmer; Oliver Gibson; Yvonne Kenworthy; Jonathan Cummings Levy; Lise Loerup; Oliver Rivero-Arias; Wai-Kit Ming; Carmelo Velardo; Lionel Tarassenko Journal: JMIR Mhealth Uhealth Date: 2018-03-20 Impact factor: 4.773
Authors: Craig H Syrop; Sarah A Wernimont; Diedre K Fleener; Joseph M Kardos; Linda M Rubenstein; Janet I Andrews Journal: J Womens Health (Larchmt) Date: 2020-08-20 Impact factor: 2.681